Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFRAIM II
2024-514344-82-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone and isavuconazole in acute respiratory decompensation, invasive mycoses, bacterial disease and 5 more (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Mortality at day 90. Started Jul 2024; status: completed.
02
Drugs
methylprednisoloneisavuconazole
03
Conditions
acute respiratory decompensationinvasive mycosesbacterial diseaseherpes simplex (HSV)Varicella zoster infection
Beyond the preview
Go deeper on 2024-514344-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514344-82-00.